Listen
Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of indication "Xeloda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen".
-
Clinical Benefit
| Substantial |
The actual benefit of XELODA is substantial. |
Clinical Added Value
| no clinical added value |
Given the lack of data showing Xeloda to be superior to 5-fluorouracil, the Committee i considers that Xeloda does not provides IAB versus this comparator. |
Contact Us
Évaluation des médicaments
